Passage Bio Receives FDA Support for Expanding Dementia Treatment Trial
PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced positive feedback from the U.S. Food and Drug Administration (FDA) on its proposal to evaluate PBFT02 for treating frontotemporal dementia (FTD) …
Passage Bio Receives FDA Support for Expanding Dementia Treatment Trial Read More